Mauvais-Jarvis P, Bercovici J P, Crepy O, Gauthier F
J Clin Invest. 1970 Jan;49(1):31-40. doi: 10.1172/JCI106219.
The metabolism of radioactive testosterone simultaneously administered intravenously and either orally or percutaneously has been studied in seven patients with the syndrome of testicular feminization and compared with that of normal males and females. This investigation was carried out in order to determine the relative contribution to urinary 17-oxo and 17beta-hydroxy androstane steroids of labeled testosterone, according to its mode of administration. In normal males the yields of urinary 5alpha-androstane-3alpha,17beta-diol (androstanediol) originating from either an intravenous or a percutaneous dose of testosterone were respectively 3 and 6 times higher than those arising from an oral dose which perfuses the liver directly. These data indicate that in normal males, testosterone might be 5alpha-hydrogenated outside the liver. By contrast in patient with feminizing testes, because the contribution to androstanediol of radioactive testosterone is identical whatever its mode of administration, the extrahepatic 5alpha-reduction of this substrate seems very unlikely. The metabolic abnormalities observed in patients with testicular feminization syndrome may be reproduced in normal males by estrogen treatment. Nevertheless, the sensitivity of the patients to estrogen seems to be 10 times greater than that of normal males. This sensitivity was appreciated from the reduction of radioactive testosterone intravenously injected to urinary 17beta-hydroxy-5alpha-androstan-3-one and androstanediol and also from the level of plasma binding for testosterone. This level was significantly higher (P < 0.05) in patients with feminizing testes than in normal males. The level increased dramatically after administration of a low dose of estrogen whereas this effect was not observed in normal males under the same experimental conditions. In light of these results the defect of extrahepatic 5alpha-reduction of testosterone observed in patients with feminizing testes does not necessarily reflect an enzymatic impairment but might be related to an abnormal synthesis of plasma binding protein(s) under the effect of circulating estrogens so that an abnormally small amount of unbound testosterone may be available in target cells for 5alpha-reduction.
在7名雄激素不敏感综合征患者中,研究了静脉内同时给予以及口服或经皮给予的放射性睾酮的代谢情况,并与正常男性和女性进行了比较。进行这项研究是为了根据睾酮的给药方式,确定标记睾酮对尿中17-氧代和17β-羟基雄甾烷类固醇的相对贡献。在正常男性中,静脉注射或经皮给予睾酮后,尿中5α-雄甾烷-3α,17β-二醇(雄甾二醇)的产量分别比直接灌注肝脏的口服剂量产生的产量高3倍和6倍。这些数据表明,在正常男性中,睾酮可能在肝脏外进行5α-氢化。相比之下,在雄激素不敏感睾丸患者中,无论给药方式如何,放射性睾酮对雄甾二醇的贡献都是相同的,因此这种底物在肝脏外的5α-还原似乎不太可能。雄激素不敏感综合征患者中观察到的代谢异常,可通过雌激素治疗在正常男性中重现。然而,患者对雌激素的敏感性似乎比正常男性高10倍。这种敏感性是通过静脉注射的放射性睾酮减少为尿中17β-羟基-5α-雄甾-3-酮和雄甾二醇以及睾酮的血浆结合水平来评估的。雄激素不敏感睾丸患者的这一水平显著高于正常男性(P < 0.05)。给予低剂量雌激素后,该水平显著升高,而在相同实验条件下,正常男性未观察到这种效应。根据这些结果,雄激素不敏感睾丸患者中观察到的睾酮肝脏外5α-还原缺陷不一定反映酶的损伤,而可能与循环雌激素作用下血浆结合蛋白的异常合成有关,从而使靶细胞中可用于5α-还原的未结合睾酮量异常少。